Organic compounds -- part of the class 532-570 series – Organic compounds – Nitriles
Reexamination Certificate
2011-04-05
2011-04-05
Chong, Yong S (Department: 1627)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitriles
C514S520000, C514S525000, C514S673000
Reexamination Certificate
active
07919647
ABSTRACT:
This invention provides a class of androgen receptor targeting agents. The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).
REFERENCES:
patent: 3239345 (1966-03-01), Unknown
patent: 3865801 (1975-02-01), Chiba et al.
patent: 3875229 (1975-04-01), Gold
patent: 4036979 (1977-07-01), Asato
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4411890 (1983-10-01), Momany et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 4977288 (1990-12-01), Kassis et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5179080 (1993-01-01), Rothkopf et al.
patent: 5441868 (1995-08-01), Lin et al.
patent: 5547933 (1996-08-01), Lin et al.
patent: 5609849 (1997-03-01), Kung
patent: 5612359 (1997-03-01), Murugesan et al.
patent: 5618698 (1997-04-01), Lin et al.
patent: 5621080 (1997-04-01), Lin et al.
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6777427 (2004-08-01), Miyakawa et al.
patent: 6838484 (2005-01-01), Steiner et al.
patent: 6899888 (2005-05-01), Steiner et al.
patent: 6960474 (2005-11-01), Salvati et al.
patent: 6995284 (2006-02-01), Dalton et al.
patent: 6998500 (2006-02-01), Dalton et al.
patent: 7026500 (2006-04-01), Dalton et al.
patent: 7041844 (2006-05-01), Miller et al.
patent: 7205437 (2007-04-01), Dalton et al.
patent: 7344700 (2008-03-01), Dalton et al.
patent: 7518013 (2009-04-01), Dalton et al.
patent: 7547728 (2009-06-01), Dalton et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 2002/0173445 (2002-11-01), Salvati et al.
patent: 2003/0232792 (2003-12-01), Dalton et al.
patent: 2004/0014975 (2004-01-01), Dalton et al.
patent: 2004/0029913 (2004-02-01), Dalton et al.
patent: 2004/0053897 (2004-03-01), Dalton et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 2004/0087810 (2004-05-01), Dalton et al.
patent: 2004/0147489 (2004-07-01), Dalton et al.
patent: 2004/0224979 (2004-11-01), Dalton et al.
patent: 2004/0260092 (2004-12-01), Miller et al.
patent: 2004/0260108 (2004-12-01), Dalton et al.
patent: 2004/0265916 (2004-12-01), Dalton et al.
patent: 2005/0038110 (2005-02-01), Steiner et al.
patent: 2005/0137172 (2005-06-01), Dalton et al.
patent: 2006/0004042 (2006-01-01), Dalton et al.
patent: 2006/0009529 (2006-01-01), Dalton et al.
patent: 2006/0035965 (2006-02-01), Dalton et al.
patent: 2006/0111441 (2006-05-01), Dalton et al.
patent: 2006/0183931 (2006-08-01), Dalton et al.
patent: 2006/0229362 (2006-10-01), Dalton et al.
patent: 2007/0066568 (2007-03-01), Dalton et al.
patent: 2007/0123563 (2007-05-01), Dalton et al.
patent: 2007/0161608 (2007-07-01), Dalton et al.
patent: 2007/0173546 (2007-07-01), Dalton et al.
patent: 2007/0281906 (2007-12-01), Dalton et al.
patent: 2009/0088480 (2009-04-01), Dalton et al.
patent: 2002364949 (2003-06-01), None
patent: 2003216174 (2003-09-01), None
patent: 2420279 (2002-02-01), None
patent: 2477737 (2003-09-01), None
patent: 2502209 (2004-04-01), None
patent: 2502355 (2004-04-01), None
patent: 2538095 (2004-04-01), None
patent: 2529464 (2005-01-01), None
patent: 0 040 932 (1981-02-01), None
patent: 0 100 172 (1984-02-01), None
patent: 00 02892 (1985-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 00198352 (1989-01-01), None
patent: 0253 503 (1991-12-01), None
patent: 668351 (1995-08-01), None
patent: 1221439 (2002-07-01), None
patent: 1401801 (2006-11-01), None
patent: 1801140 (2007-06-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: 59-033250 (1984-02-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98/05962 (1998-02-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 01/27086 (2001-04-01), None
patent: WO 01/27622 (2001-04-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01/28990 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 01/34563 (2001-05-01), None
patent: WO 01/68603 (2001-09-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/00617 (2002-01-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO 02/22585 (2002-03-01), None
patent: WO 03/11302 (2003-02-01), None
patent: WO 03/49675 (2003-06-01), None
patent: WO 03/065992 (2003-08-01), None
patent: WO 03/074449 (2003-09-01), None
patent: WO 03/077919 (2003-09-01), None
patent: WO 03/77919 (2003-09-01), None
patent: WO 2004/034978 (2004-04-01), None
patent: WO 2004/035736 (2004-04-01), None
patent: WO 2005/000794 (2005-01-01), None
patent: WO 2005/060647 (2005-07-01), None
U.S. Appl. No. 09/935,044, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/935,045, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, Apr. 7, 2002.
Berger et al., “Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate”, Invest. Urol, (1975), 1391, 10-16.
Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, “Resolution of the Nonsteroidal Antiandrogen -4′-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enuntiomer ”.
D. McKillop, et al., “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
Lonnquist et al., 1995, Nature Med. 1:950.
Matsumoto, 1994, “Hormonal therapy of male hypogonadism” Endocrinol. Met. Clin. N. Am. 23:857-75.
Pelleymounter et al., 1995, “Effects of the obese gene product on body weight regulation in ob/ob mice.”Science269:540-543.
Singh et al., 2003, “Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.”Endocrinology, 144(11):5081-8.
Sefton, 1987, “Implantable pumps.” CRC Crit. Ref. Biomed. Eng. 14:201.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL. United States, Apr. 7, 2002.
Leonid Kirkovsky, et al., “[123I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
David T. Baird and Anna F. Glasier, “Hormonal Contraception—Drug Therapy”, The New England Journal of Medicine , May 27, 1993, pp. 1543-1549.
F.C. W. Wu, “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”,
Dalton James T.
He Yali
Miller Duane D.
Yin Donghua
Chong Yong S
Cohen Mark S.
Pearl Cohen Zedek Latzer LLP
University of Tennessee Research Foundation
LandOfFree
Selective androgen receptor modulators and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective androgen receptor modulators and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective androgen receptor modulators and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641205